Sensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib era.
Texto
Documentos relacionados
The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response
Imatinib dose escalation in two patients with chronic myeloid leukemia, with low trough imatinib plasma levels measured at various intervals from the beginning of therapy and
Determination of serum levels of imatinib mesylate in patients with chronic myeloid leukemia: validation and application of a new analytical method to control
Determination of serum levels of imatinib mesylate in patients with chronic myeloid leukemia: validation and application of a new analytical method to monitor treatment
O objetivo deste trabalho é relatar o caso clínico de transplante dentário autógeno, realizado em sessão única, como alternativa terapêutica aos demais métodos
These learning environmental factors appear as relevant in students’ achievement goals, and have been related to academic results (Urdan 2010) and
The identification of BCR-ABL expression as the defining leu- kemogenic event in chronic myeloid leukemia (CML) and the introduction of BCR-ABL tyrosine kinase inhibitors (TKIs)
Multiple BCR-ABL kinase domain mutations confer polyclonal resis- tance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid